The prognosis for breast cancer can vary widely depending on the subtype:
ER-positive/PR-positive: Generally has a better prognosis because these cancers tend to grow more slowly and respond well to hormonal therapies. HER2-positive: Prognosis has improved significantly with HER2-targeted therapies, though it is still considered more aggressive than hormone receptor-positive cancers. TNBC: Often has a poorer prognosis due to its aggressive nature and lack of targeted therapies, but research is ongoing to find more effective treatments.
